SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc. is a clinical-stage biopharmaceutical company headquartered in New York, specializing in the development of innovative cancer immunotherapies targeting various malignancies. The company's lead candidate, galinpepimut-S (GPS), is a peptide-based immunotherapeutic agent that targets the Wilms tumor 1 (WT1) antigen and is currently undergoing Phase III clinical trials for acute myeloid leukemia (AML) and other development phases for ovarian cancer. Additionally, SELLAS is advancing nelipepimut-S in Phase 2b trials for breast cancer. The company has a strategic partnership with Merck & Co. to assess GPS in combination with the PD1 blocker pembrolizumab across multiple cancer indications. SELLAS has received orphan and fast track designations from the FDA for galinpepimut-S, highlighting its potential to enhance existing treatments and improve patient outcomes, particularly in AML and malignant pleural mesothelioma. The company maintains a close collaboration with Memorial Sloan-Kettering Cancer Center, where it licensed its lead product.